Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [2][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance than the market, with the Shenwan Beauty Care Index declining by 4.8% from March 13 to March 20, 2026, underperforming the Shenwan A Index by 0.7 percentage points [4][5]. - Upcoming earnings reports from key companies such as Lin Qingxuan and Shangmei will be critical for assessing market trends and performance [4][9]. - Notable company performances include: - Aimei Ke reported a revenue of 2.453 billion yuan for 2025, down 18.94% year-on-year, with a net profit of 1.291 billion yuan, down 34.05% [10]. - Juzi Biotechnology's revenue was 5.519 billion yuan, a slight decrease of 0.4%, with a net profit of 1.915 billion yuan, down 7.2% [10] [11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector is currently underperforming the market, with specific indices showing declines [4][5]. - The Shenwan Cosmetics Index fell by 3.4%, while the Shenwan Personal Care Index dropped by 4.4% [4]. Company Highlights - Aimei Ke's Q4 2025 revenue was 588 million yuan, down 9.61% year-on-year, with a net profit of 198 million yuan, down 46.85% [10]. - Juzi Biotechnology's effective skincare products generated 4.337 billion yuan in revenue, a 0.8% increase, while medical dressings saw a 4.8% decline [11]. Market Trends - The report highlights the importance of upcoming earnings disclosures from major companies, which are expected to provide insights into market recovery and performance [4][9]. - The overall retail sales of cosmetics in January-February 2026 grew by 4.5%, indicating a relative resilience in the beauty sector compared to the overall retail market [14]. E-commerce and Brand Performance - The report provides data on e-commerce performance, noting that domestic brands are gaining market share, with significant growth in GMV for brands like Shangmei [13]. - The report emphasizes the competitive landscape, with domestic brands increasingly challenging international players in market share [21][23].

Core Viewpoint - The company, Fenbi, anticipates a decline in both revenue and net profit for the fiscal year ending December 31, 2025, primarily due to intensified competition in the Chinese civil service examination training industry [1][3]. Group 1: Financial Performance - For the fiscal year ending December 31, 2025, Fenbi expects to generate no less than 2.656 billion yuan in revenue, representing a decrease of no more than 4.8% compared to 2.79 billion yuan for the fiscal year ending December 31, 2024 [1]. - The projected net profit for 2025 is expected to be no less than 185 million yuan, a decline of no more than 22.8% from 240 million yuan in 2024 [1]. - Adjusted net profit for 2025 is anticipated to be no less than 270 million yuan, down by no more than 25.5% from 363 million yuan in 2024, mainly due to reduced revenue [1]. Group 2: Market Position and Competition - Fenbi's revenue for 2024 was 2.79 billion yuan, a decrease of 7.7% from 3.021 billion yuan in 2023, while the annual profit increased by 27.0% to 240 million yuan [3]. - The company specializes in civil service examination training and also covers various vocational examination training projects, including public institution recruitment, teacher recruitment, graduate school entrance exams, and accounting [3]. - Fenbi, along with Huatu and Zhonggong Education, is recognized as one of the "big three" in civil service training, and a strategic partnership was established between Fenbi and Huatu in December 2025, potentially altering the long-standing "tripod" market structure [3][4]. Group 3: Strategic Initiatives - The partnership with Huatu is viewed as a milestone that could fundamentally change the competitive landscape of the civil service education industry [4]. - Fenbi is increasing its investment in AI research and development, reallocating 60.8 million HKD of unutilized IPO funds, with 12 million HKD specifically for AI vertical model development and commercialization, and 48.8 million HKD for AI talent and infrastructure [4]. Group 4: Market Performance - Fenbi was listed on the Hong Kong Stock Exchange in January 2023 at an issue price of 9.9 HKD per share, achieving a market capitalization of 23.28 billion HKD on the first trading day [4]. - As of February 24, 2024, the stock price had fallen to 1.59 HKD per share, resulting in a market capitalization of only 3.51 billion HKD, indicating a market value loss of 19.77 billion HKD and an approximate 84% decline in stock price since listing [4].

Core Viewpoint - Jingtai Technology has successfully delivered an automated workstation for formula stability testing to BASF, marking a significant advancement in chemical automation and validating its technical and commercial capabilities [1][2]. Group 1: Company Achievements - Jingtai Technology's automated laboratory solutions have been instrumental in various fields, including drug development, petrochemicals, new energy, and new materials, providing high-precision research data [2]. - The successful implementation of the collaboration with BASF is attributed to Jingtai's unique modular standard platform and agile customization capabilities, which have been successfully delivered in high-value areas such as new drug development and chemical synthesis [2][3]. - The automated laboratory not only standardizes experimental operations but also generates high-quality structured data, which is essential for developing proprietary AI models in research and development [3]. Group 2: Market Position and Expansion - Jingtai Technology has established a competitive edge in the field of chemical automation, having served major enterprises and top research institutions, including international pharmaceutical companies and Sinopec [3]. - The business model of "standardized platform + agile customization" allows Jingtai to expand its market boundaries from pharmaceutical research to large-scale chemical and new energy sectors, tapping into trillion-level markets [3]. - BASF, as a global leader in the chemical industry, employs approximately 112,000 people and is projected to achieve global sales of €65.3 billion in 2024, highlighting the scale and significance of the partnership with Jingtai Technology [3].

Group 1 - The company plans to raise 373 million yuan to enhance its vehicle communication product capacity and AI research capabilities [1] - The company clarified that its wholly-owned subsidiary, Gaoxin Intelligent IoT, has no plans for an IPO [1] - The T-BOX product has obtained EU NG eCall certification, allowing it to collaborate with domestic automakers for international sales, including major clients like Geely and Changan [1] Group 2 - The company's stock price has shown volatility, closing at 6.05 yuan on February 6, 2026, with a daily decline of 1.47% and a net outflow of 30.84 million yuan in principal funds [2] - As of February 12, 2026, the stock price was 6.18 yuan, reflecting a 0.65% change over five days, but a 13.57% decline over 20 days [2] - Technical indicators suggest the stock is below the middle band of the Bollinger Bands, with a weak MACD indicator and a short-term resistance level around 7.4 yuan [2] Group 3 - The company's 2025 earnings forecast indicates expected revenue between 1.9 billion and 2.1 billion yuan, representing a year-on-year growth of 34% to 48%, despite facing losses for the fourth consecutive year [3] - The narrowing of losses is attributed to growth in the vehicle terminal business and optimized cost control [3] - Previous quarterly reports showed revenue of 1.318 billion yuan and a net profit of 63.55 million yuan, indicating significant year-on-year growth, but the company has not achieved profitability for the full year, raising concerns about high accounts receivable and other financial risks [3]

Core Viewpoint - Recently, Lizhu Group released an investor research record detailing the progress of its innovative drug, Lakanqita monoclonal antibody, in the immunology field and vaccine development [1] Immunology Field - Lakanqita monoclonal antibody is the company's flagship product, currently undergoing clinical research for moderate to severe psoriasis and ankylosing spondylitis [1] - The psoriasis indication has been submitted for market approval and included in the CDE priority review, with the earliest approval expected by the end of this year [1] - The ankylosing spondylitis indication is expected to be submitted for market approval in Q2 2026 [1] - Phase III clinical research shows a PASI 100 response rate of 49.5% for the Lakanqita monoclonal antibody group, significantly better than the 40.2% response rate for Secukinumab [1] - The company has initiated overseas collaboration discussions to explore the development of new indications in the future [1] Vaccine Development - The company is advancing the development of an inactivated influenza vaccine and recombinant human follicle-stimulating hormone injection [1] - The quadrivalent recombinant protein influenza vaccine is expected to enter Phase II clinical trials in the first half of 2026 [1] - The recombinant human follicle-stimulating hormone injection is anticipated to receive market approval within 2026 [1] - The company emphasizes the continued use of AI technology to enhance research and development efficiency, shorten development cycles, and further strengthen market competitiveness [1]

Group 1 - The core achievement of the company is the successful delivery of an automated workstation for formulation stability testing to BASF, a global leader in the chemical industry, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration signifies a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] - The company's modular standard platform and agile customization capabilities have been successfully implemented in high-value fields such as new drug development and chemical synthesis, ensuring efficient deployment and stable operation [2] Group 2 - The automated laboratory solutions have been adopted by various large enterprises and top research institutions, including international pharmaceutical companies and major universities, expanding the company's business boundaries from pharmaceutical research to large-scale chemical and new energy markets [3] - The company aims to deepen strategic collaboration with global industry leaders, accelerating the technological iteration of intelligent laboratories and providing core infrastructure for innovation in industrial research efficiency [3] - The integration of AI in research is positioning the company's automated laboratories as essential infrastructure for future AI-driven research, establishing a unique competitive barrier in the market [2]

本自願公告乃由晶泰控股有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 作 出，以 知 會 股 東 及 潛 在 投 資 者 有 關 本 集 團 的 最 新 業 務 發 展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 XtalPi Holdings Limited 晶泰控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2228） 自願性公告 晶 泰 科 技 機 器 人 實 驗 室 落 地 巴 斯 夫， 全球技術領導力獲化工業頂級背書 本公司董事會（「董事會」）欣 然 宣 布，近 日，本 集 團 已 成 功 向 全 球 化 工 巨 頭 巴 斯 夫(BASF)交 付 了 一 種 配 方 穩 定 性 測 試 自 動 化 工 作 站，助 力 巴 斯 夫 構 建 起「樣 品 管 理－測 試 分 析－數 據 管 理」全 鏈 路 的 自 動 化 ...

Group 1 - The company, CaiXun Co., Ltd. (300634.SZ), has announced a plan to issue convertible bonds to unspecified investors, with a total fundraising amount not exceeding RMB 1.46 billion (including principal) [1] - The net proceeds from the bond issuance, after deducting issuance costs, will be invested in several projects, including the construction of a smart computing center, the R&D upgrade of the Rich AIBox platform, and the development of enterprise-level AI intelligent applications [1]

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median stock price increase for the top 10 innovative drug companies was 57.9%, while in 2025, this surged to a median increase of 495.41%, with the highest increase reaching 1824% [2] Group 1: Top Performing Companies - The top-performing stock in 2025 was Beihai Kangcheng, with an astonishing annual increase of 1824%, surprising many in the market [4] - Following Beihai Kangcheng, the second highest was Sanleaf Biotech, which saw an increase of 870%, despite facing significant operational challenges [10] - Yaojie Ankang ranked third with a 773% increase, although its valuation raised concerns due to its limited clinical progress [12] - Heber Pharmaceuticals achieved a 553% increase, driven by its dual-engine model of R&D and business development [16] - Xuan Bamboo Biotech, a newly listed company, experienced a 507% increase, attributed to its new stock status and positive clinical data [20] Group 2: Market Dynamics and Trends - The market has seen a trend of speculative trading, with some companies experiencing price surges not necessarily backed by fundamental improvements [4] - The rise of companies like Heber Pharmaceuticals and Rongchang Biotech illustrates that long-term undervalued firms can achieve significant valuation recovery through continuous R&D and commercialization breakthroughs [4][30] - The innovative drug sector's growth is heavily influenced by liquidity and market sentiment, with many price increases based on speculative expectations rather than solid fundamentals [39] Group 3: Company-Specific Developments - Beihai Kangcheng's stock price recovery was linked to strategic capital injections, resolving its cash flow crisis [7] - Sanleaf Biotech's stock price rebound was primarily driven by its RSV vaccine pipeline, despite facing significant financial pressures [10][11] - Yaojie Ankang's rapid valuation increase raised questions about its sustainability, given its limited clinical advancements [13][14] - Heber Pharmaceuticals' growth was supported by strategic partnerships and a robust technology platform, enhancing investor confidence [18][19] - Rongchang Biotech's stock performance was bolstered by successful product approvals and strategic financing, improving its market outlook [31]

Core Insights - The article highlights the journey and achievements of Cai Tong, the founder of Yabao Chemical, emphasizing his unique interdisciplinary background and strategic vision in the fine chemical industry [2][3]. Company Development - Yabao Chemical has focused on deepening its core business layout, particularly in the pharmaceutical sector, by signing a strategic cooperation agreement with leading domestic pharmaceutical company Heng Rui Medicine to enhance the quality and efficiency of its pharmaceutical business [3]. - The company has established its Malta base as a bridge for international business, equipped with EU GMP certification and formulation repackaging capabilities, facilitating domestic pharmaceutical companies' expansion into overseas markets [3]. - In the agrochemical intermediate sector, Yabao Chemical is concentrating on innovative, green, and efficient CDMO services, maintaining strategic partnerships with international agrochemical firms such as Corteva, Bayer, and FMC to solidify its leading position in niche markets [3]. Innovation and Investment - During the 14th Five-Year Plan period, Yabao Chemical has invested nearly 600 million yuan in research and development, prioritizing technological innovation as a core growth engine and establishing an AI research laboratory to build an intelligent R&D system [3]. - The company aims to create a diversified business structure encompassing pharmaceuticals, agrochemicals, and other sectors, referred to as "Pharmaceuticals + Agrochemicals + X" [3]. Recognition and Contributions - Cai Tong has received various accolades for his contributions to the industry and society, including the 2010 Taicang City First Lou Dong Talent Award and the 2013 Outstanding Person in China's Service Outsourcing Award [4]. - He holds multiple positions in educational and industry associations, contributing to talent cultivation and regional industrial collaboration [4].